Biotech Values

[kiroset]

>The Fibrogen presentation is up on retailroadshow:

I viewed the presentation today and did a bit more research -

For anemia -
The biological mechanism around HIF is interesting. Nice clinical data so far. Market potential here is huge. Some competition (GSK, Akebia). Safety looks like it could be a risk.

I recognize the safety profile on FG-4592 has come back clean so far, with quite a few patients treated. But I learned that this is a second generation molecule. FG-2216 was put on clinical hold for awhile and apparently discontinued due to a patient death.

http://www.ajkd.org/article/S0272-6386%2811%2901568-X/fulltext

Combine that with the recent announcement from Akebia - which also experienced a patient death in their phase 2. One starts to wonder if this class of molecules is safe enough.

Has Fibrogen ever talked about why FG-4592 is safer than FG-2216? They have slightly different molecular structures.

Everything else about the drug looks stellar.


For fibrosis -

Looks like there is a lot of room for improvement over current treatments. There is some compelling data here - and ITMN was bought by Roche for $8+ billion